Login to Your Account



Phase III Fail in Advanced Tumors

Yervoy Ploy Decoy? Pre-chemo Prostate Market Size in Dispute

By Randy Osborne
Staff Writer

Friday, September 13, 2013

As approved prostate cancer drugs duke it out in the prostate cancer space and scramble for pre-chemotherapy patients, Bristol-Myers Squibb Co.’s near-miss Phase III results with the anti-CTLA-4 drug Yervoy (ipilimumab) in advanced disease left some cause in the data for optimism that the melanoma therapy might fare better in a separate trial against earlier stages of the tumor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription